Cite This Page
Bibliographic details for Caspasecleavable peptidedoxorubicin conjugate in conjunction with CD47antagonizing nanocage therapeutics pertaining to immunemediated avoidance of intestinal tract cancer
- Page name: Caspasecleavable peptidedoxorubicin conjugate in conjunction with CD47antagonizing nanocage therapeutics pertaining to immunemediated avoidance of intestinal tract cancer
- Author: OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors
- Publisher: OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, .
- Date of last revision: 21 January 2024 09:12 UTC
- Date retrieved: 9 June 2024 12:29 UTC
- Permanent URL: https://news.npo.digital/index.php?title=Caspasecleavable_peptidedoxorubicin_conjugate_in_conjunction_with_CD47antagonizing_nanocage_therapeutics_pertaining_to_immunemediated_avoidance_of_intestinal_tract_cancer&oldid=585805
- Page Version ID: 585805
Citation styles for Caspasecleavable peptidedoxorubicin conjugate in conjunction with CD47antagonizing nanocage therapeutics pertaining to immunemediated avoidance of intestinal tract cancer
APA style
Caspasecleavable peptidedoxorubicin conjugate in conjunction with CD47antagonizing nanocage therapeutics pertaining to immunemediated avoidance of intestinal tract cancer. (2024, January 21). OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . Retrieved 12:29, June 9, 2024 from https://news.npo.digital/index.php?title=Caspasecleavable_peptidedoxorubicin_conjugate_in_conjunction_with_CD47antagonizing_nanocage_therapeutics_pertaining_to_immunemediated_avoidance_of_intestinal_tract_cancer&oldid=585805.
MLA style
"Caspasecleavable peptidedoxorubicin conjugate in conjunction with CD47antagonizing nanocage therapeutics pertaining to immunemediated avoidance of intestinal tract cancer." OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . 21 Jan 2024, 09:12 UTC. 9 Jun 2024, 12:29 <https://news.npo.digital/index.php?title=Caspasecleavable_peptidedoxorubicin_conjugate_in_conjunction_with_CD47antagonizing_nanocage_therapeutics_pertaining_to_immunemediated_avoidance_of_intestinal_tract_cancer&oldid=585805>.
MHRA style
OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, 'Caspasecleavable peptidedoxorubicin conjugate in conjunction with CD47antagonizing nanocage therapeutics pertaining to immunemediated avoidance of intestinal tract cancer', OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , 21 January 2024, 09:12 UTC, <https://news.npo.digital/index.php?title=Caspasecleavable_peptidedoxorubicin_conjugate_in_conjunction_with_CD47antagonizing_nanocage_therapeutics_pertaining_to_immunemediated_avoidance_of_intestinal_tract_cancer&oldid=585805> [accessed 9 June 2024]
Chicago style
OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, "Caspasecleavable peptidedoxorubicin conjugate in conjunction with CD47antagonizing nanocage therapeutics pertaining to immunemediated avoidance of intestinal tract cancer," OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , https://news.npo.digital/index.php?title=Caspasecleavable_peptidedoxorubicin_conjugate_in_conjunction_with_CD47antagonizing_nanocage_therapeutics_pertaining_to_immunemediated_avoidance_of_intestinal_tract_cancer&oldid=585805 (accessed June 9, 2024).
CBE/CSE style
OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors. Caspasecleavable peptidedoxorubicin conjugate in conjunction with CD47antagonizing nanocage therapeutics pertaining to immunemediated avoidance of intestinal tract cancer [Internet]. OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, ; 2024 Jan 21, 09:12 UTC [cited 2024 Jun 9]. Available from: https://news.npo.digital/index.php?title=Caspasecleavable_peptidedoxorubicin_conjugate_in_conjunction_with_CD47antagonizing_nanocage_therapeutics_pertaining_to_immunemediated_avoidance_of_intestinal_tract_cancer&oldid=585805.
Bluebook style
Caspasecleavable peptidedoxorubicin conjugate in conjunction with CD47antagonizing nanocage therapeutics pertaining to immunemediated avoidance of intestinal tract cancer, https://news.npo.digital/index.php?title=Caspasecleavable_peptidedoxorubicin_conjugate_in_conjunction_with_CD47antagonizing_nanocage_therapeutics_pertaining_to_immunemediated_avoidance_of_intestinal_tract_cancer&oldid=585805 (last visited June 9, 2024).
BibTeX entry
@misc{ wiki:xxx,
author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
title = "Caspasecleavable peptidedoxorubicin conjugate in conjunction with CD47antagonizing nanocage therapeutics pertaining to immunemediated avoidance of intestinal tract cancer --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
year = "2024",
url = "https://news.npo.digital/index.php?title=Caspasecleavable_peptidedoxorubicin_conjugate_in_conjunction_with_CD47antagonizing_nanocage_therapeutics_pertaining_to_immunemediated_avoidance_of_intestinal_tract_cancer&oldid=585805",
note = "[Online; accessed 9-June-2024]"
}
When using the LaTeX package url (\usepackage{url} somewhere in the preamble) which tends to give much more nicely formatted web addresses, the following may be preferred:
@misc{ wiki:xxx,
author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
title = "Caspasecleavable peptidedoxorubicin conjugate in conjunction with CD47antagonizing nanocage therapeutics pertaining to immunemediated avoidance of intestinal tract cancer --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
year = "2024",
url = "\url{https://news.npo.digital/index.php?title=Caspasecleavable_peptidedoxorubicin_conjugate_in_conjunction_with_CD47antagonizing_nanocage_therapeutics_pertaining_to_immunemediated_avoidance_of_intestinal_tract_cancer&oldid=585805}",
note = "[Online; accessed 9-June-2024]"
}
